Our Process & Overview
Current Investment Opportunities
Healthcare Innovations Alliance
Medical Innovation Summit
Top 10 Medical Innovations
Blog & News
Therapeutics & Diagnostics
Germline Mutations and Variants in SDH Genes in Cowden and Cowden-like Syndromes
Charis Eng, MD, PhD
Frank Weber, MD
Contact Innovation Manager
What is it? What does it do?
The invention includes a means of using mutational variants in the succinate dehydrogenase gene (SDH) for diagnosis and prognosis of those who have heightened risk for breast, thyroid and renal neoplasms when presenting with a PTEN mutation negative, Cowden Syndrome/Cowden-like syndrome (CS/CSL) germline background.
Why is it better?
Instructs first associations of germline variations in SDHx genes as candidate predisposing and modifier genes for CS/CSL-related malignancy risks.
In heritable cancer syndromes this is the first clinically useful modifier (SDHx variants) of a germline PTEN mutation especially for breast cancer risk. Importantly, if a patient has a germline PTEN mutation, they have an 85% lifetime risk of female breast cancer. However, a treating clinician cannot say she will be that 85% of that 15%. With a germline SDH variant together with a germline PTEN mutation, the lifetime risk of female breast cancer is 100% - which approaches a long sought prognostic holy grail for medical geneticists.
What is its current status?
Prototype assay developed
Other Technologies by Inventor
Other Technologies by Innovation Manager
Genetic Mechanism Augments DHT Synthesis in CRPC
Method of Treating Genitourinary Disorder Using Mesenchymal Stem Cells and Cultured Media
Method for Diagnosing PTEN Hamartoma Tumor Syndrome (PHTS)
Get in Touch With Us